Gan & Lee Pharmaceuticals to Reveal Key Data on Three Innovations at ADA's 84th Scientific Sessions

Gan & Lee Pharmaceuticals has announced the presentation of three significant research abstracts at the forthcoming American Diabetes Association's (ADA) 84th Scientific Sessions, set to take place both in-person and virtually in Orlando, Florida, from June 21-24, 2024. The abstracts, which highlight the company's investigational drugs, will be published on the journal Diabetes® website and presented live on June 22 in the Poster Hall.

The first trial, a phase 1b/2a study, focused on GZR18, a novel GLP-1 analog, evaluated in Chinese subjects with obesity or overweight. The trial investigated both once- and bi-weekly dosing regimens, aiming to determine the safety, efficacy, and pharmacokinetic profiles of GZR18. This innovative drug represents a significant step forward in the management of obesity, offering potential new treatment options for a condition that affects millions globally.

In another set of pre-clinical studies, researchers evaluated GZR4, an investigational once-weekly insulin analog. These studies aimed to characterize the molecular and pharmacological properties of GZR4, which could offer a more convenient dosing schedule for patients requiring insulin therapy. The findings from these pre-clinical evaluations suggest that GZR4 has promising pharmacokinetic and pharmacodynamic characteristics, positioning it as a potential new option for diabetes management.

Additionally, pre-clinical studies were conducted on GZR33, an ultra-long-acting basal insulin, and its premixed formulation, GZR101. These studies aimed to evaluate the long-acting properties and potential benefits of these formulations, which could significantly improve the management of blood glucose levels in diabetic patients. By providing more stable and prolonged insulin action, GZR33 and GZR101 could enhance the quality of life for those requiring insulin therapy.

Gan & Lee Pharmaceuticals, a company renowned for developing the first Chinese domestic insulin analog, continues to expand its portfolio with six core insulin products. These include long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and mixed protamine human insulin injection (30R) (Similin®30). Furthermore, the company offers two approved medical devices in China: the reusable insulin injection pen (GanleePen) and the disposable pen needle (GanleeFine®).

Significantly, Gan & Lee ranked second overall and first among domestic companies in China's second Volume Based Procurement (VBP) in 2024, in terms of procurement demand for insulin analogs. The company's international presence is also strengthening, with the disposable pen needle (GanleeFine®) receiving approval from the US Food and Drug Administration (FDA) in 2020 and a GMP inspection approval from the European Medicines Agency (EMA) in 2024.

Looking ahead, Gan & Lee remains committed to comprehensive coverage in diabetes treatment and aims to become a world-class pharmaceutical company. The company plans to actively develop new chemical entities and biological drugs, focusing on metabolic diseases, cardiovascular diseases, and other therapeutic areas, thereby broadening its treatment portfolio and enhancing its global competitiveness.